Maravai Lifesciences Holdings (MRVI) FCF Margin (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly FCF Margin of 6.42% for Q1 2026, up 2953.0% year-over-year from 0.21% in Q1 2025, and up 109.15% quarter-over-quarter from 70.19% in Q4 2025.
Powered by 
Analysis
Maravai Lifesciences Holdings (MRVI) FCF Margin (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' FCF Margin history runs 7 years deep, the most recent figure standing at 6.42% for Q1 2026.
- In Q1 2026, FCF Margin rose 2953.0% year-over-year to 6.42%; the TTM figure through Mar 2026 stood at 27.19% (down 2953.0% YoY), while the FY2025 annual figure was 38.08%, down 3995.0% from the prior year.
- FCF Margin for Q1 2026 stood at 6.42%, up from 70.19% in the prior quarter.
- The five-year high for FCF Margin was 97.7% in Q1 2023, with the low at 70.19% in Q4 2025.
- The 5-year median for FCF Margin is 6.58% (2024), against an average of 15.64%.
- The sharpest annual moves came in 2022 and 2024: FCF Margin surged 4068 bps in 2022, then slumped 11582 bps in 2024.
- Maravai Lifesciences Holdings' FCF Margin stood at 53.01% in 2022, then surged by 39 bps to 73.55% in 2023, then sank by 84 bps to 11.59% in 2024, then sank by 706 bps to 70.19% in 2025, then soared by 109 bps to 6.42% in 2026.
- Business Quant data shows MRVI's FCF Margin at 6.42% in Q1 2026, 70.19% in Q4 2025, and 19.11% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Maravai Lifesciences Holdings | 1.09 Bn | 1.02 Bn | 20.65 Mn | 7.04% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.04% |
| Mar 31, 2026 | 6.42% |
| Dec 31, 2025 | -49.90% |
| Sep 30, 2025 | -45.18% |
| Jun 30, 2025 | -27.72% |
| Mar 31, 2025 | -29.65% |
| Dec 31, 2024 | -36.22% |
| Sep 30, 2024 | 6.58% |
| Jun 30, 2024 | 11.35% |
| Mar 31, 2024 | -22.02% |
| Dec 31, 2023 | -12.15% |
| Sep 30, 2023 | -2.48% |
| Jun 30, 2023 | -8.51% |
| Mar 31, 2023 | 97.70% |
| Dec 31, 2022 | 45.49% |
| Sep 30, 2022 | 54.16% |
| Jun 30, 2022 | 66.99% |
| Mar 31, 2022 | 65.31% |
| Dec 31, 2021 | 23.24% |
| Sep 30, 2021 | 50.89% |